Literature DB >> 19685298

High-throughput quantitative bioluminescence imaging for assessing tumor burden.

Angelina Contero1, Edmond Richer, Ana Gondim, Ralph P Mason.   

Abstract

Bioluminescence imaging (BLI) has emerged during the past 5 years as the preeminent method for rapid, cheap, facile screening of tumor growth and spread in mice. Both subcutaneous and orthotopic tumor models are readily observed with high sensitivity and reproducibility. User-friendly commercial instruments exist and, increasingly, luciferase-expressing tumor cells are available in academic institutions or commercially. There is an increasing literature on routine use of BLI for assessing chemotherapeutic efficacy, drug combinations, dosing, and timing. In addition, BLI may be applied to more sophisticated questions of molecular biology by including specific promoter sequences. This chapter will describe routine methods used to support multiple investigators in our small animal imaging resource.

Entities:  

Mesh:

Year:  2009        PMID: 19685298      PMCID: PMC3027220          DOI: 10.1007/978-1-60327-321-3_4

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  11 in total

1.  Use of firefly luciferase in ATP-related assays of biomass, enzymes, and metabolites.

Authors:  A Lundin
Journal:  Methods Enzymol       Date:  2000       Impact factor: 1.600

Review 2.  Molecular imaging in living subjects: seeing fundamental biological processes in a new light.

Authors:  Tarik F Massoud; Sanjiv S Gambhir
Journal:  Genes Dev       Date:  2003-03-01       Impact factor: 11.361

Review 3.  It's not just about anatomy: in vivo bioluminescence imaging as an eyepiece into biology.

Authors:  Christopher H Contag; Brian D Ross
Journal:  J Magn Reson Imaging       Date:  2002-10       Impact factor: 4.813

4.  Optical imaging of Renilla luciferase reporter gene expression in living mice.

Authors:  S Bhaumik; S S Gambhir
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-18       Impact factor: 11.205

5.  The use of histone deacetylase inhibitor FK228 and DNA hypomethylation agent 5-azacytidine in human bladder cancer therapy.

Authors:  Jose A Karam; Jinhai Fan; Jennifer Stanfield; Edmond Richer; Elie A Benaim; Eugene Frenkel; Peter Antich; Arthur I Sagalowsky; Ralph P Mason; Jer-Tsong Hsieh
Journal:  Int J Cancer       Date:  2007-04-15       Impact factor: 7.396

6.  Oxygen sensitivity of reporter genes: implications for preclinical imaging of tumor hypoxia.

Authors:  Ivana Cecic; Denise A Chan; Patrick D Sutphin; Pritha Ray; Sanjiv Sam Gambhir; Amato J Giaccia; Edward E Graves
Journal:  Mol Imaging       Date:  2007 Jul-Aug       Impact factor: 4.488

7.  Microregional distributions of glucose, lactate, ATP and tissue pH in experimental tumours upon local hyperthermia and/or hyperglycaemia.

Authors:  C Schaefer; W K Mayer; W Krüger; P Vaupel
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

8.  Bioluminescent molecular imaging of endogenous and exogenous p53-mediated transcription in vitro and in vivo using an HCT116 human colon carcinoma xenograft model.

Authors:  Wenge Wang; Wafik S El-Deiry
Journal:  Cancer Biol Ther       Date:  2003 Mar-Apr       Impact factor: 4.742

Review 9.  Validity of bioluminescence measurements for noninvasive in vivo imaging of tumor load in small animals.

Authors:  Clara P W Klerk; Renée M Overmeer; Tatjana M H Niers; Henri H Versteeg; Dick J Richel; Tessa Buckle; Cornelis J F Van Noorden; Olaf van Tellingen
Journal:  Biotechniques       Date:  2007-07       Impact factor: 1.993

10.  Validating bioluminescence imaging as a high-throughput, quantitative modality for assessing tumor burden.

Authors:  Zain Paroo; Robert A Bollinger; Dwaine A Braasch; Edmond Richer; David R Corey; Peter P Antich; Ralph P Mason
Journal:  Mol Imaging       Date:  2004-04       Impact factor: 4.488

View more
  11 in total

Review 1.  Lung cancer cell lines as tools for biomedical discovery and research.

Authors:  Adi F Gazdar; Luc Girard; William W Lockwood; Wan L Lam; John D Minna
Journal:  J Natl Cancer Inst       Date:  2010-08-02       Impact factor: 13.506

2.  In vivo bioluminescence imaging of tumor hypoxia dynamics of breast cancer brain metastasis in a mouse model.

Authors:  Debabrata Saha; Henry Dunn; Heling Zhou; Hiroshi Harada; Masahiro Hiraoka; Ralph P Mason; Dawen Zhao
Journal:  J Vis Exp       Date:  2011-10-03       Impact factor: 1.355

3.  Novel immunocompetent murine models representing advanced local and metastatic pancreatic cancer.

Authors:  Elizabeth C Little; Cindy Wang; Patricia M Watson; Dennis K Watson; David J Cole; E Ramsay Camp
Journal:  J Surg Res       Date:  2011-11-10       Impact factor: 2.192

4.  A perspective on vascular disrupting agents that interact with tubulin: preclinical tumor imaging and biological assessment.

Authors:  Ralph P Mason; Dawen Zhao; Li Liu; Mary Lynn Trawick; Kevin G Pinney
Journal:  Integr Biol (Camb)       Date:  2011-02-14       Impact factor: 2.192

5.  Imaging beta-galactosidase activity in human tumor xenografts and transgenic mice using a chemiluminescent substrate.

Authors:  Li Liu; Ralph P Mason
Journal:  PLoS One       Date:  2010-08-06       Impact factor: 3.240

6.  Dynamic bioluminescence and fluorescence imaging of the effects of the antivascular agent Combretastatin-A4P (CA4P) on brain tumor xenografts.

Authors:  Li Liu; Ralph P Mason; Barjor Gimi
Journal:  Cancer Lett       Date:  2014-10-08       Impact factor: 8.679

Review 7.  Non-Invasive Evaluation of Acute Effects of Tubulin Binding Agents: A Review of Imaging Vascular Disruption in Tumors.

Authors:  Li Liu; Devin O'Kelly; Regan Schuetze; Graham Carlson; Heling Zhou; Mary Lynn Trawick; Kevin G Pinney; Ralph P Mason
Journal:  Molecules       Date:  2021-04-27       Impact factor: 4.411

8.  Comparison of optical and power Doppler ultrasound imaging for non-invasive evaluation of arsenic trioxide as a vascular disrupting agent in tumors.

Authors:  Mustafa K Alhasan; Li Liu; Matthew A Lewis; Jennifer Magnusson; Ralph P Mason
Journal:  PLoS One       Date:  2012-09-28       Impact factor: 3.240

9.  Tubulin-destabilizing agent BPR0L075 induces vascular-disruption in human breast cancer mammary fat pad xenografts.

Authors:  Li Liu; Haley Beck; Xiaolei Wang; Hsing-Pang Hsieh; Ralph P Mason; Xinli Liu
Journal:  PLoS One       Date:  2012-08-24       Impact factor: 3.240

10.  Multimodal imaging guided preclinical trials of vascular targeting in prostate cancer.

Authors:  James Kalmuk; Margaret Folaron; Julian Buchinger; Roberto Pili; Mukund Seshadri
Journal:  Oncotarget       Date:  2015-09-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.